The significance of elevated tumor markers among patients with interstitial lung diseases

Byoung Soo Kwon1,2, Eun Sun Kim1,2, Sung Yoon Lim1,2, Myung Jin Song1,2, Yeon Wook Kim1,2, Hyung-Jun Kim1,2, Yeon Joo Lee1,2, Jong Sun Park1,2, Young-Jae Cho1,2, Ho Il Yoon1,2, Choon-Taek Lee1,2 & Jae Ho Lee1,2*

The clinical implication of using serum tumor markers in patients with interstitial lung disease (ILD) is inconclusive. In this retrospective study, we analyzed the data of 1176 subjects (294 with ILDs and 882 healthy controls). Eligible patients were who had at least one or more available tumor marker results [carbohydrate antigen (CA) 19-9, CA 125, and carcinoembryonic antigen (CEA)] with no evidence of malignancies or other benign diseases that could be related to the increasing concentration of the values. The healthy controls selected from a health screening program were also screened for the presence of active cancer, and matched at a ratio of 1:3 with age and sex. The proportion of patients with abnormal values in the ILD group (121, idiopathic pulmonary fibrosis (IPF); 173, non-IPF-ILDs) was higher than in the matched control group (CEA, 21.5% vs. 5.5%; CA 19-9, 27.9% vs. 4.0%; CA 125, 36.4% vs. 2.0%). In the multivariable analysis, higher CEA levels were associated with shorter survival after adjusting for age, sex, lung function, and ILD subtypes (hazard ratio: 2.323, 95% confidence interval: 1.271–4.248, \( P = 0.006 \)). In subgroup analysis, CEA remained a prognostic factor in patients with non-IPF-ILDs, but not in those with IPF.

Interstitial lung diseases (ILDs) encompass numerous types of disorders characterized by inflammation and/or fibrosis in the lung interstitium. Idiopathic pulmonary fibrosis (IPF) is a major subset of idiopathic ILDs and causes significant mortality and morbidities. The clinical trajectory of patients with IPF is highly variable, but advanced IPF is expected to have poor survival of 2–3 years after diagnosis. Further, approximately one-third of non-IPF-ILDs showed a progressive phenotype similar to IPF. High-resolution computed tomography (HRCT) scans and pulmonary function tests (PFT) are an important part of monitoring the disease. However, the costs, radiation hazards, and suboptimal PFT results due to impaired lung functions, limit its use and necessitate other more easily measured prediction modalities. As a result, serum tumor markers have been proposed as a potential tool for predicting and monitoring patients at risk of disease progression or death.

To date, tumor markers are widely used for cancer screening programs, including colorectal, ovarian, and lung cancers, and cancers of the pancreato-biliary systems, etc. However, most tumor markers are not ‘tumor-specific’. Rather, they are ‘tumor-associated’; their serum concentrations originate from the proliferated epithelial cells regardless of the specific organ or system. In addition, these biomarkers may be elevated in benign diseases. Similarly, patients with chronic lung diseases without any evidence of malignancies may also show abnormal levels of tumor marker compared to the healthy population. Additionally, previous studies have demonstrated that these values are associated with pulmonary functions, disease progression, and increased mortality in patients with IPF.

Despite the previous studies, no consensus has been established for the use of tumor markers. Furthermore, the relevance of tumor markers in patients with IPF and non-IPF-ILDs has yet to be determined. Thus, in the current study, we first investigated the differences in tumor marker concentrations between patients with ILDs and healthy populations. Then, we examined the prognostic roles of tumor markers in patients with various ILDs.

1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si 13620, Gyeonggi-do, Korea. 2Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. *email: jhlee7@snubh.org
Results

Baseline characteristics. In the unmatched cohort, healthy controls were more likely to be female and were younger than the ILDs group. After propensity score matching, a total of 294 patients with ILDs and 882 individuals in the healthy population were identified (Fig. 1). The mean age of all subjects was 68.1 years, and 66.4% were men (Table 1).

The number of patients with available CEA, CA 19-9, and CA 125 results were 1143, 1034, and 348, respectively. Although the levels of tumor markers of the ILDs group were significantly higher than the matched control group, the median values of both groups were within normal limits. When the tumor markers were analyzed as dichotomized variables, a significantly higher proportion of patients in the ILD group showed abnormal values compared to individuals in the control group (Table 1).

![Flowchart of study design](https://doi.org/10.1038/s41598-022-20683-w)
Among the patients with ILDs, 121 patients (41.2%) were diagnosed with IPF, and the remaining 173 patients (58.8%) had non-IPF-ILDs. The IPF group was more likely to be older, male predominant, and had a higher proportion of ever-smoking history. There were no differences in the serum tumor marker levels between the groups in both continuous and categorical variables (Table 2).

**Survival and prognostic factors.** The median follow-up duration of the ILD group was 34.4 months, and 73 (24.8%) patients died. Patients with a high CEA concentration showed poorer survival than those with normal values (median survival of 78.0 months vs. not reached, \( P < 0.001 \), Fig. 2).

In univariate analysis, lower forced vital capacity (FVC), diagnosis of IPF, and higher values of tumor markers (CEA, CA 19-9, and CA 125) were significantly associated with mortality. In the multivariate analysis, we chose only CEA among the tumor markers because of missing CA 19-9 and CA 125 data. Consequently, a higher CEA level was significantly associated with mortality in patients with ILDs \( [ \text{hazard ratio (HR)} 2.323, 95\% \text{ confidence interval (CI)} 1.271–4.248, P = 0.006] \) after adjusting for age, sex, FVC, and ILD types (Table 3).

In subgroup analysis according to the ILD subtypes, lower FVC was related to mortality in patients with IPF \( [ \text{HR} 0.947, 95\% \text{ CI} 0.926–0.969, P < 0.001] \). In contrast, patients with lower FVC showed a trend toward shorter survival; however, this trend did not have statistical significance in non-IPF-ILDs. Instead, higher CEA was associated with poorer survival in patients with non-IPF-ILDs \( [ \text{HR} 3.938, 95\% \text{ CI} 1.707–9.084, P = 0.001] \), Table 4.

### Table 2. Baseline characteristics of 294 patients according to the diagnosis. Data are expressed as mean ± SD, median (interquartile range), or frequency (%).

|                | Total (n = 294) | IPF (n = 121) | Non-IPF-ILDs (n = 173)\( ^a \) | \( P \)-value |
|----------------|----------------|--------------|-------------------------------|--------------|
| Age (yrs)      | 68.2 ± 12.9    | 72.5 ± 10.0  | 65.2 ± 13.9                   | < 0.001      |
| Sex, male (%)  | 192 (65.3)     | 90 (74.4)    | 102 (59.0)                    | 0.006        |
| Smoking (%)    | 162 (58.1)     | 79 (68.1)    | 83 (50.9)                     | 0.004        |
| **PFT**        |                |              |                               |              |
| FVC (L)        | 83.7 ± 28.4    | 81.1 ± 18.2  | 80.8 ± 19.7                   | 0.899        |
| DLCO (mL/min)  | 74.1 ± 23.6    | 78.7 ± 21.1  | 72.4 ± 24.4                   | 0.089        |
| **Tumor marker** |               |              |                               |              |
| CEA (n = 266)  | 2.8 (1.7–4.9)  | 3.0 (2.2–4.8) | 2.7 (1.5–5.1)                | 0.236        |
| CEA (%)        | 65 (24.4)      | 24 (22.2)    | 41 (25.9)                     | 0.487        |
| CA19-9 (n = 154) | 14.1 (5.9–34.8) | 17.3 (6.3–80.3) | 11.3 (5.7–31.0)              | 0.166        |
| CA19-9 (%)     | 37 (24.0)      | 16 (26.7)    | 21 (22.3)                     | 0.556        |
| CA125 (n = 55) | 24.2 (11.2–59.4) | 26.5 (17.4–65.0) | 21.3 (10.7–60.1)          | 0.405        |
| CA125 (%)      | 20 (36.4)      | 6 (46.2)     | 14 (33.3)                     | 0.401        |

Figure 2. Comparison of survival in 294 patients with ILDs according to the serum carcinoembryonic antigen level. **CEA** carcinoembryonic antigen.
In this study, we compared the serum concentration of tumor markers between patients with ILDs and healthy subjects, and evaluated the prognostic role of these values, particularly in patients with ILDs. After matching with age and sex, all tumor marker levels were significantly higher in ILD groups than in healthy controls. Further, a higher level of CEA was associated with mortality in patients with ILDs, even after adjusting for the baseline demographics, ILD subtypes, and lung functions.

Currently, tumor markers are widely used in cancer screening programs. However, their diagnostic performance for cancer screening is limited. Instead, tumor markers are used as a tool to monitor treatment response or tumor recurrence. Moreover, because CA 19-9, CA 125, and CEA are synthesized in epithelial cells of various tissues, elevated tumor markers can be observed in nonmalignant diseases. Chung et al. conducted a retrospective study using data of 25,786 subjects with health check-ups, and reported elevated CEA in 585 (2.3%) participants without malignancy compared to 12 (0.1%) participants with malignancy. Associated conditions of COPD, smoking, or pulmonary inflammations were identified in 61.8% of the non-cancer subjects with elevated CEA. In a retrospective study, Hao et al. compared the CEA levels in patients with a benign or malignant disease with healthy controls. The results showed that serum CEA concentrations were high even with no evidence of malignancy. CA 125, which is used for the detection of ovarian cancer, can also be elevated in benign diseases. In a population-based cohort study of 50,780 women in the United Kingdom, Funston et al. reported that 1,321 (2.6%) subjects with elevated CA 125 were categorized with non-ovarian causes. Among them, 127 (9.6%) patients had associated respiratory causes. Similarly, Lee et al. investigated the positive rate of CA 19-9. Of a total of 58,498 subjects, 581 (1.0%) had elevated CA 19-9, and only four patients were diagnosed with cancer. In our study, the proportion of subjects in the unmatched cohort without cancer and with elevated tumor markers was similar to the aforementioned studies. Although these proportions tended to increase after the propensity matching with age and sex, the tumor markers of patients with ILDs were significantly higher than those of the control group.

Many previous studies have assessed the association between tumor markers and clinical outcomes in patients with ILDs. Maher et al. retrospectively analyzed a prospective cohort of 312 patients with IPF and reported the following results:

### Table 3. Prognostic factor for mortality in 294 patients with ILDs.

| Univariate analysis | Multivariate analysis |
|---------------------|-----------------------|
| **IPF**             | **Non-IPF-ILDs**       |
| **HR**              | **95% CI**            | **HR**              | **95% CI** |
| **P-value**         | **HR**                | **95% CI**         |
| **P-value**         | **P-value**           |
| Age 1.010           | 0.991–1.028           | 0.300              |
| Sex, male 1.356     | 0.822–2.237           | 0.233              |
| Smoking 1.254       | 0.780–2.015           | 0.351              |
| PFT FVC (%) 0.963   | 0.949–0.978           | <0.001             |
| DLCO (%) 0.990      | 0.976–1.084           | 0.149              |
| ILD type, IPF 1.754 | 1.101–2.796           | 0.018              |
| Tumor markers       |                       |
| CEA 2.482           | 1.522–4.049           | <0.001             |
| CA 19-9 2.540       | 1.230–5.247           | 0.012              |
| CA 125 6.624        | 1.238–35.446          | 0.027              |
| PFT FVC (%) 0.949   | 0.929–0.969           | <0.001             |
| CEA 1.362           | 0.658–2.818           | 0.405              |
| Multivariate analysis |                       |                     |
| FVC (%) 0.947       | 0.926–0.969           | <0.001             |
| CEA 3.938           | 1.707–9.084           | 0.001              |

### Table 4. Prognostic factor for mortality according to the specific diagnosis.

| Univariate analysis | Multivariate analysis |
|---------------------|-----------------------|
| **IPF**             | **Non-IPF-ILDs**       |
| **HR**              | **95% CI**            | **HR**              | **95% CI** |
| **P-value**         | **HR**                | **95% CI**         |
| **P-value**         | **P-value**           |
| Age 0.999           | 0.969–1.030           | 0.952              |
| Sex, male 1.030     | 0.505–2.100           | 0.935              |
| FVC (%) 0.949       | 0.929–0.969           | <0.001             |
| CEA 1.362           | 0.658–2.818           | 0.405              |
| Multivariate analysis |                       |                     |
| FVC (%) 0.947       | 0.926–0.969           | <0.001             |
| CEA 3.938           | 1.707–9.084           | 0.001              |

### Discussion

In this study, we compared the serum concentration of tumor markers between patients with ILDs and healthy subjects, and evaluated the prognostic role of these values, particularly in patients with ILDs. After matching with age and sex, all tumor marker levels were significantly higher in ILD groups than in healthy controls. Further, a higher level of CEA was associated with mortality in patients with ILDs, even after adjusting for the baseline demographics, ILD subtypes, and lung functions.

Currently, tumor markers are widely used in cancer screening programs. However, their diagnostic performance for cancer screening is limited. Instead, tumor markers are used as a tool to monitor treatment response or tumor recurrence. Moreover, because CA 19-9, CA 125, and CEA are synthesized in epithelial cells of various tissues, elevated tumor markers can be observed in nonmalignant diseases. Chung et al. conducted a retrospective study using data of 25,786 subjects with health check-ups, and reported elevated CEA in 585 (2.3%) participants without malignancy compared to 12 (0.1%) participants with malignancy. Associated conditions of COPD, smoking, or pulmonary inflammations were identified in 61.8% of the non-cancer subjects with elevated CEA. In a retrospective study, Hao et al. compared the CEA levels in patients with a benign or malignant disease with healthy controls. The results showed that serum CEA concentrations were high even with no evidence of malignancy. CA 125, which is used for the detection of ovarian cancer, can also be elevated in benign diseases. In a population-based cohort study of 50,780 women in the United Kingdom, Funston et al. reported that 1,321 (2.6%) subjects with elevated CA 125 were categorized with non-ovarian causes. Among them, 127 (9.6%) patients had associated respiratory causes. Similarly, Lee et al. investigated the positive rate of CA 19-9. Of a total of 58,498 subjects, 581 (1.0%) had elevated CA 19-9, and only four patients were diagnosed with cancer. In our study, the proportion of subjects in the unmatched cohort without cancer and with elevated tumor markers was similar to the aforementioned studies. Although these proportions tended to increase after the propensity matching with age and sex, the tumor markers of patients with ILDs were significantly higher than those of the control group.

Many previous studies have assessed the association between tumor markers and clinical outcomes in patients with ILDs. Maher et al. retrospectively analyzed a prospective cohort of 312 patients with IPF and reported the following results:
that baseline CA 19-9 and changes in CA 125 were potential biomarkers for disease progression and overall survival, respectively\(^{22}\). Dai et al. found that CA 19-9, CA 125, and CEA were higher in patients with IPF than in patients with other chronic respiratory diseases\(^{29}\). Similarly, tumor markers were also elevated in patients with non-IPF-ILD\(^{30–32}\). However, even with emerging research, the results are inconclusive, and the question of which biomarkers give the most convincing evidence should be further elucidated. In our study, we found that all tumor markers were significantly higher in the ILD group than in the controls. Further, the proportion of patients with elevations greater than the upper limit of tumor markers was 21.5–36.4\%. Nevertheless, there were no differences between patients with IPF and non-IPF-ILDs. According to previous studies, the levels of tumor markers that originated from epithelial cells reflect the severity of disease\(^{21}\). Thus, tumor markers, especially CEA, were negatively correlated with lung functions\(^{20,21}\). Taken together, the similar tumor marker levels in the IPF and non-IPF-ILDs groups noted in our study might be because there were no differences in lung function between the two groups.

We focused on the clinical relevance of CEA in the multivariable analysis because of missing CA 19-9 and CA 125 data. In the results, higher CEA levels showed poorer survival in patients with ILDs as a whole, even after adjusting for confounders. Evidence has shown that distal airways and type II alveolar cells play a critical role in the pathogenesis of lung fibrosis\(^{34–36}\). Fahim et al. demonstrated that strong CEA staining was present in the epithelial cell lining of the respiratory bronchioles and the honeycomb cysts of lung tissue in patients with IPF\(^{21}\). Therefore, although the mechanism of CEA elevation in ILDs is still unclear, it could be postulated that the serum concentration of CEA is linked to the severity of fibrosis\(^{27,34,35}\). However, in the subgroup analysis of our study, the IPF group did not show sustained results. A possible explanation for this discrepancy is because of the small sample size of the IPF group.

There are several limitations in our study. First, data on the smoking status of unmatched healthy controls were not collected. It is known that serum CEA concentrations are increased in heavy smokers\(^{37}\). Nevertheless, the tumor markers in the control group were similar to the previous population-based studies. In addition, smoking status between the two groups were not significantly different (51% in healthy controls vs. 58.1% in ILDs, \(P = 0.052\), data not shown). Second, dynamic changes of tumor markers were not evaluated in the current study. For instance, Maher et al. reported that the serial rising concentration of CA 125 is a prognostic marker in patients with IPF\(^{22}\). Although our study did not provide information on the association between serial tumor marker changes and clinical outcomes, the results give us useful information for predicting long term prognosis at the time of patient diagnosis. This is possible because we used blood test results taken as close as possible to the date of the diagnosis of ILD. Third, other potential serum biomarkers for predicting clinical courses of patients with ILDs such as Krebs von den Lungen-6 or serum surfactant protein, were not assessed in the current study. Fourth, the number of patients with specific disease entities of non-IPF ILDs was relatively small to draw robust conclusions. Moreover, because of the heterogeneity of it nature, these patients might show a different pattern of association between serum CEA levels and clinical outcomes. Nevertheless, the CEA levels at the time of diagnosis were found to be significant even after adjusting for the clinical relevant factors. Considering the simplicity of measurement, CEA could be a useful biomarker for identifying poor prognostic subgroups.

In conclusion, the serum levels of CEA, CA 19-9, and CA 125 of patients with ILDs were significantly higher than the age- and sex-matched healthy subjects. In addition, baseline CEA at ILD diagnosis showed potential as a predictor of prognosis, particularly in patients with non-IPF-ILDs. Further research with sufficient sample size is required in order to verify these results for patients with each specific disease.

**Methods**

**Study population.** In this retrospective study, we reviewed 8338 patients diagnosed with respiratory diseases and 107,681 subjects who underwent a health screening program between May 2003 and February 2021. Subjects with at least one or more available data on tumor markers [carbohydrate antigen (CA) 19-9, CA 125, and carcinoembryonic antigen (CEA)] were eligible for the study. To minimize the effect of chronic respiratory diseases on tumor markers, we excluded patients with chronic obstructive pulmonary disease (COPD), bronchiectasis, nontuberculous mycobacterial pulmonary disease, and tuberculosis-destroyed lung. In addition, patients with active cancer who were treated with anticancer therapy or those with shorter than one-year interval between the date of ILD diagnosis and date of cancer diagnosis were excluded. Similarly, patients without malignant diseases but with a date of tumor marker evaluation beyond 1-year before or after ILD diagnosis were also excluded. IPF was diagnosed based on the criteria of the 2018 American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS), and Latin American Thoracic Society (ALAT) statement\(^{36}\). Patients with ILDs who did not fulfill the ATS/ERS/JRS/ALAT diagnostic criteria were categorized as non-IPF-ILD.

The tumor markers of eligible patients were compared with those of healthy controls without active cancers using propensity score matching at a ratio of 1:3 with age and sex.

The study was approved by the Institutional Review Board (IRB) of Seoul National University of Bundang Hospital (IRB No. B-2012-654-004) and is consistent with the principles of the Declaration of Helsinki. Informed consent was waived by the IRB of Seoul National University of Bundang Hospital due to the retrospective nature of the study.

**Measurement of serum tumor markers.** Serum concentrations of CA 19-9, CA 125, and CEA were measured by electrochiluminescence immunoassay or immunoradio metric assay. The reference values were in the range 0–37 U/ml for CA 19-9, 0–35 U/ml for CA 125, and 0–5 ng/ml for CEA.
Statistical analysis. Continuous variables were expressed as mean ± standard deviation (SD) or median (interquartile range, IQR), and analyzed by Student’s t-test. Categorical variables were presented as frequency and compared by the chi-squared test. The propensity score matching was performed by sex and age at the test date.

The overall survival was estimated using the Kaplan–Meier method. The survival time was calculated from the date of ILD diagnosis to the last hospital visit or time of death. Cox proportional hazards regression analysis was used to identify significant variables related to survival. Variables with a P-value of < 0.1 in the unadjusted analysis and known as having clinical relevance were chosen in multivariable analysis using the backward log-likelihood ratio method. A P-value of < 0.05 was considered significant. Statistical analyses were performed using IBM SPSS version 25 (SPSS, Inc., Chicago IL, USA), R-studio, and Prism version 5 (GraphPad, San Diego, CA, USA).

Data availability
The data that support the findings of this study are not openly available due to the fact that consent to sharing data was not obtained from participants. However, the datasets used and analyzed in the current study are available from the corresponding author on reasonable request.

Received: 22 January 2022; Accepted: 16 September 2022
Published online: 06 October 2022

References
1. Wells, A. U. & Hirani, N. Interstitial lung disease guideline. Thorax 63, v1–v58. https://doi.org/10.1136/thx.2008.101691 (2008).
2. Fernández Pérez, E. R. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: A population-based study. Chest 137, 129–137. https://doi.org/10.1378/chest.09-1902 (2010).
3. Ley, B., Collard, H. R. & King, T. E. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183, 431–440. https://doi.org/10.1164/rccm.201006-0894CI (2011).
4. Nasser, M. et al. Progressive fibrosing interstitial lung disease: A clinical cohort (the PROGRESS study). Eur. Respir. J. 57, 2002718. https://doi.org/10.1183/13993003.02718-2020 (2021).
5. Wijnenbeek, M. et al. Progressive fibrosing interstitial lung diseases: Current practice in diagnosis and management. Curr. Med. Res. Opin. 35, 2015–2024. https://doi.org/10.1185/03007995.2019.1647040 (2019).
6. Kwon, B. S. et al. Progressive fibrosing interstitial lung disease: Prevalence and clinical outcome. Respir. Res. 22, 282. https://doi.org/10.1186/s12391-021-01879-6 (2021).
7. Collard, H. R. et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 168, 538–542. https://doi.org/10.1164/rccm.200211-131OC (2003).
8. Sumikawa, H. et al. Computed tomography findings in pathological usual interstitial pneumonia. Am. J. Respir. Crit. Care Med. 177, 433–439. https://doi.org/10.1164/rccm.200609-1169OC (2008).
9. Kim, J.-E. et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J. Gastroenterol. Hepatol. 19, 182–186. https://doi.org/10.1111/j.1440-1746.2004.02319.x (2004).
10. Hawley, S. E., Vernon, S. W., Levin, B. & Vallejo, B. Prevalence of colorectal cancer screening in a large medical organization. Cancer Epidemiol. Biomark. Prevent. 13, 314–319. https://doi.org/10.1158/1055-9965.epi-09-202 (2004).
11. Lee, J. H. et al. Should a colonoscopy be recommended for healthy individuals with increased carcinoembryonic antigen levels? A case-control study. Dig. Dis. Sci. 56, 2396–2403. https://doi.org/10.1007/s10620-011-1666-1 (2011).
12. Lim, Y. K., Kam, M. H. & Eu, K. W. Carcinoembryonic antigen screening: How far should we go?. Singap. Med. J. 50, 862–865 (2009).
13. Suresh, M. R. Classification of tumor markers. Anticancer Res. 16, 2273–2277 (1996).
14. Rizeq, B., Zakaria, Z. & Ouhtit, A. Towards understanding the mechanisms of actions of carcinoembryonic antigen-related cell adhesion molecule 6 in cancer progression. Cancer Sci. 109, 33–42. https://doi.org/10.1111/cas.13437 (2018).
15. Hung, C.-L. et al. Beyond malignancy: The role of carbohydrate antigen 125 in heart failure. Biomark. Res. 1, 25. https://doi.org/10.1186/2050-7771-1-25 (2013).
16. Lee, J. Y., Lee, D. C. & Lee, J. W. Serum carcinoembryonic antigen is associated with non-alcoholic fatty liver disease in healthy Korean non-smokers. Clin. Chem. Lab. Med. 51, 1499–1504. https://doi.org/10.1515/cclm-2012-0585 (2013).
17. Levy, C. et al. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig. Dis. Sci. 50, 1734–1740. https://doi.org/10.1007/s10620-005-2927-2 (2005).
18. Yang, Y. et al. Serum carcinoembryonic antigen elevation in benign lung diseases. Sci. Rep. 11, 19044. https://doi.org/10.1038/s41598-021-98513-8 (2021).
19. Funston, G. et al. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Med. 17, e1003295. https://doi.org/10.1371/journal.pmed.1003295 (2020).
20. d’Alessandro, M. et al. Systematic review and metaanalysis of oncomarkers in IPF patients and serial changes of oncomarkers in a prospective Italian real-life case series. Cancers https://doi.org/10.3390/cancers13030331 (2021).
21. Fahim, A. et al. Serum carcinoembryonic antigen correlates with severity of idiopathic pulmonary fibrosis. Respirilogy (Carlton, Vic) 17, 1247–1252. https://doi.org/10.1111/j.1440-1843.2012.02231.x (2012).
22. Maher, T. M. et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: An analysis from the multicentre PROFILE cohort study. Lancet Respir. Med. 5, 946–955. https://doi.org/10.1016/S2213-2600(17)30430-7 (2017).
23. Sekiguchi, M. & Matsuda, T. Limited usefulness of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for gastrointestinal and whole-body cancer screening. Sci. Rep. 10, 18202. https://doi.org/10.1038/s41598-020-73519-8 (2020).
24. Duff, M. J. et al. Tumor markers in pancreatic cancer: A European Group on Tumor Markers (EGTM) status report. Ann. Oncol. 21, 441–447. https://doi.org/10.1093/annonc/mdn332 (2010).
25. Matsuoka, Y. et al. Normal bronchial mucus contains high levels of cancer-associated antigens, CA125, CA19-9, and carcinoembryonic antigen. Cancer 65, 506–510. https://doi.org/10.1002/1097-0142(19900201)65:3%3c506::aid-cncr28228056022%3e3.0.co;2-0 (1990).
26. Chung, S. False-positive elevations in carcinoembryonic antigen levels at a health screening center. Immo 9, 146–152. https://doi.org/10.3343/imoa.2019.9.3.146 (2019).
27. Hao, C., Zhang, G. & Zhang, L. Serum CEA levels in 49 different types of cancer and noncancer diseases. Prog. Mol. Biol. Transl. Sci. 162, 213–227. https://doi.org/10.1016/bspb.2018.12.011 (2019).
28. Lee, S. P. et al. Usefulness of carbohydrate antigen 19-9 test in healthy people and necessity of medical follow-up in individuals with elevated carbohydrate antigen 19-9 level. Korean J. Fam. Med. 40, 314–322. https://doi.org/10.14082/kjfm.18.0057 (2019).
29. Dai, H. et al. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirilogy (Carlton, Vic) 19, 707–713. https://doi.org/10.1111/resp2.12317 (2014).
30. Zheng, M. et al. Serum KL-6, CA19-9, CA125 and CEA are diagnostic biomarkers for rheumatoid arthritis-associated interstitial lung disease in the Chinese population. *Rheumatol. Ther.* **8**, 517–527. https://doi.org/10.1007/s40744-021-00288-x (2021).
31. Zhu, D. et al. Elevated carcinoembryonic antigen predicts rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis. *Rheumatology (Oxford)* **60**, 3896–3903. https://doi.org/10.1093/rheumatology/keaa819 (2021).
32. Jin, Q. et al. Value of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in evaluating severity and prognosis of connective tissue disease-associated interstitial lung disease. *Arch. Rheumatol.* **33**, 190–197. https://doi.org/10.5606/ArchRheuma trol.2018.6419 (2018).
33. Shi, L. et al. Increases in tumor markers are associated with primary Sjögren's syndrome-associated interstitial lung disease. *Ther. Adv. Chronic Dis.* **11**, 204062230944802. https://doi.org/10.1177/204062230944802 (2020).
34. Seibold, M. A. et al. The idiopathic pulmonary fibrosis honeycomb cyst contains a mucociliary pseudostratified epithelium. *PLoS ONE* **8**, e58658. https://doi.org/10.1371/journal.pone.0058658 (2013).
35. Evans, C. M. et al. Idiopathic pulmonary fibrosis: A genetic disease that involves mucociliary dysfunction of the peripheral airways. *Physiol. Rev.* **96**, 1567–1591. https://doi.org/10.1152/physrev.00004.2016 (2016).
36. Yao, C. et al. Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* **203**, 707–717. https://doi.org/10.1164/rcrm.202004-1274OC (2020).
37. Stevens, D., Mackay, C., Group, B. P. S. Increased carcinoembryonic antigen in heavy cigarette smokers. *Lancet* **302**, 1238–1239 (1973).
38. Raghu, G. et al. Diagnosis of idiopathic pulmonary fibrosis: An official ATS/ERS/JRS/ALAT clinical practice guideline. *Am. J. Respir. Crit. Care Med.* **198**, e44–e68. https://doi.org/10.1164/rrcm.201807-1255ST (2018).

**Author contributions**
J.H.L. is the guarantor of the paper and takes responsibility for the integrity of the work as a whole. B.S.K. takes responsibility for the data analysis. B.S.K. and J.H.L. contributed to the study design. B.S.K., E.S.K., S.Y.L., M.J.S., Y.W.K., H.J.K., Y.J.L., J.S.P., Y.J.C., H.I.Y., C.T.L., and J.H.L. contributed to the interpretation of results. B.S.K. and J.H.L. drafted the initial manuscript. All authors discussed the results and reviewed the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Correspondence and requests for materials should be addressed to J.H.L.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022